Armed with deals, dol­lars and the promise of up­com­ing da­ta, Zymeworks files $75M IPO

A lit­tle more than a year ago, as Zymeworks CEO Ali Tehrani was reel­ing in a $61.5 mil­lion crossover round, the biotech CEO told me that he had a two-year run­way and a shot at be­ing op­por­tunis­tic in fil­ing for an IPO. This morn­ing, Tehrani con­clud­ed that the time was right—or at least nec­es­sary.

Zymeworks $ZYME has been blitz­ing its way through a se­ries of part­ner­ships and ex­pan­sion projects fo­cused on its bis­pe­cif­ic an­ti­bod­ies and armed AD­Cs, two plat­forms Zymeworks will now de­pend on to raise at least $75 mil­lion in an IPO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.